Market revenue in 2022 | USD 919.1 million |
Market revenue in 2030 | USD 1,563.1 million |
Growth rate | 6.9% (CAGR from 2022 to 2030) |
Largest segment | Lead identification & candidate optimization |
Fastest growing segment | Other Associated Workflow |
Historical data covered | 2018 - 2021 |
Base year for estimation | 2022 |
Forecast period covered | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Target Identification & Screening, Target Validation & Functional Informatics, Lead Identification & Candidate Optimization, Preclinical Development, Other Associated Workflow |
Key market players worldwide | Albany Molecular Research, Evotec SE, Labcorp Holdings Inc, GenScript ProBio, Pharmaceutical Product Development, Charles River Laboratories International Inc, Wuxi AppTec Co Ltd, Merck & Co Inc, Thermo Fisher Scientific Inc, Dalton Pharma Services, Jubilant Biosys, Qiagen NV, Eurofins Scientific SE, Dr. Reddy’s Laboratories, Pharmaron Beijing Co Ltd Ordinary Shares - Class H, TCG Lifesciences, Syngene, Oncodesign, DiscoveRX, Domainex |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to drug discovery outsourcing market will help companies and investors design strategic landscapes.
Lead identification & candidate optimization was the largest segment with a revenue share of 32.46% in 2022. Horizon Databook has segmented the Europe drug discovery outsourcing market based on target identification & screening, target validation & functional informatics, lead identification & candidate optimization, preclinical development, other associated workflow covering the revenue growth of each sub-segment from 2018 to 2030.
While the European drug market appears to be shrinking, the BRIC economies are continuously experiencing higher sales growth. The total pharmaceutical sales of BRIC countries were expected to grow at a rate of 15% per year from 2011 to 2016 and the sales in the European countries (i.e. Germany, France, Italy, United Kingdom, and Spain) were expected to drop at a rate of 1.2% over the same period.
According to a study, total pharma spending of EU has decreased from 17% in 2011 to 13% of the global market in 2016, still it is expected that EU market will continue to be a major source of revenue for branded pharmaceutical companies.
EU has taken initiatives in various projects and is discovering and developing various drugs including antibiotic drugs to increase the growth of drug discovery services within the country.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe drug discovery outsourcing market , including forecasts for subscribers. This continent databook contains high-level insights into Europe drug discovery outsourcing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account